<?xml version='1.0' encoding='utf-8'?>
<document id="27128004"><sentence text="Impact on abiraterone pharmacokinetics and safety: Open-label drug-drug interaction studies with ketoconazole and rifampicin."><entity charOffset="10-21" id="DDI-PubMed.27128004.s1.e0" text="abiraterone" /><entity charOffset="97-109" id="DDI-PubMed.27128004.s1.e1" text="ketoconazole" /><entity charOffset="114-124" id="DDI-PubMed.27128004.s1.e2" text="rifampicin" /><pair ddi="false" e1="DDI-PubMed.27128004.s1.e0" e2="DDI-PubMed.27128004.s1.e0" /><pair ddi="false" e1="DDI-PubMed.27128004.s1.e0" e2="DDI-PubMed.27128004.s1.e1" /><pair ddi="false" e1="DDI-PubMed.27128004.s1.e0" e2="DDI-PubMed.27128004.s1.e2" /><pair ddi="false" e1="DDI-PubMed.27128004.s1.e1" e2="DDI-PubMed.27128004.s1.e1" /><pair ddi="false" e1="DDI-PubMed.27128004.s1.e1" e2="DDI-PubMed.27128004.s1.e2" /></sentence><sentence text="We evaluated the impact of a strong CYP3A4 inhibitor, ketoconazole, and a strong inducer, rifampicin, on the pharmacokinetic (PK) exposure of abiraterone in two studies in healthy men"><entity charOffset="54-66" id="DDI-PubMed.27128004.s2.e0" text="ketoconazole" /><entity charOffset="90-100" id="DDI-PubMed.27128004.s2.e1" text="rifampicin" /><entity charOffset="142-153" id="DDI-PubMed.27128004.s2.e2" text="abiraterone" /><pair ddi="false" e1="DDI-PubMed.27128004.s2.e0" e2="DDI-PubMed.27128004.s2.e0" /><pair ddi="false" e1="DDI-PubMed.27128004.s2.e0" e2="DDI-PubMed.27128004.s2.e1" /><pair ddi="false" e1="DDI-PubMed.27128004.s2.e0" e2="DDI-PubMed.27128004.s2.e2" /><pair ddi="false" e1="DDI-PubMed.27128004.s2.e1" e2="DDI-PubMed.27128004.s2.e1" /><pair ddi="false" e1="DDI-PubMed.27128004.s2.e1" e2="DDI-PubMed.27128004.s2.e2" /></sentence><sentence text=" All subjects received 1,000 mg of abiraterone acetate on Days 1 and 14"><entity charOffset="35-54" id="DDI-PubMed.27128004.s3.e0" text="abiraterone acetate" /></sentence><sentence text=" Study A subjects (n = 20) received 400 mg ketoconazole on Days 11-16"><entity charOffset="43-55" id="DDI-PubMed.27128004.s4.e0" text="ketoconazole" /></sentence><sentence text=" Study B subjects (n = 19) received 600 mg rifampicin on Days 8-13"><entity charOffset="43-53" id="DDI-PubMed.27128004.s5.e0" text="rifampicin" /></sentence><sentence text=" Serial PK sampling was done on Days 1 and 14" /><sentence text=" Study A: When given with ketoconazole, abiraterone exposure increased by 9% for maximum plasma concentration (Cmax ) and 15% for area under the plasma concentration-time curve from 0 to time of the last quantifiable concentration (AUClast ) and AUC from time 0 to infinity (AUC∞ ) compared to abiraterone acetate alone"><entity charOffset="26-38" id="DDI-PubMed.27128004.s7.e0" text="ketoconazole" /><entity charOffset="40-51" id="DDI-PubMed.27128004.s7.e1" text="abiraterone" /><entity charOffset="294-313" id="DDI-PubMed.27128004.s7.e2" text="abiraterone acetate" /><pair ddi="false" e1="DDI-PubMed.27128004.s7.e0" e2="DDI-PubMed.27128004.s7.e0" /><pair ddi="false" e1="DDI-PubMed.27128004.s7.e0" e2="DDI-PubMed.27128004.s7.e1" /><pair ddi="false" e1="DDI-PubMed.27128004.s7.e0" e2="DDI-PubMed.27128004.s7.e2" /><pair ddi="false" e1="DDI-PubMed.27128004.s7.e1" e2="DDI-PubMed.27128004.s7.e1" /><pair ddi="false" e1="DDI-PubMed.27128004.s7.e1" e2="DDI-PubMed.27128004.s7.e2" /></sentence><sentence text=" Study B: When given with rifampicin, abiraterone exposure was reduced to 45% for Cmax and AUC∞ and to 42% for AUClast compared to abiraterone acetate alone"><entity charOffset="26-36" id="DDI-PubMed.27128004.s8.e0" text="rifampicin" /><entity charOffset="38-49" id="DDI-PubMed.27128004.s8.e1" text="abiraterone" /><entity charOffset="131-150" id="DDI-PubMed.27128004.s8.e2" text="abiraterone acetate" /><pair ddi="false" e1="DDI-PubMed.27128004.s8.e0" e2="DDI-PubMed.27128004.s8.e0" /><pair ddi="false" e1="DDI-PubMed.27128004.s8.e0" e2="DDI-PubMed.27128004.s8.e1" /><pair ddi="false" e1="DDI-PubMed.27128004.s8.e0" e2="DDI-PubMed.27128004.s8.e2" /><pair ddi="false" e1="DDI-PubMed.27128004.s8.e1" e2="DDI-PubMed.27128004.s8.e1" /><pair ddi="false" e1="DDI-PubMed.27128004.s8.e1" e2="DDI-PubMed.27128004.s8.e2" /></sentence><sentence text=" Ketoconazole had no clinically meaningful impact on abiraterone exposure"><entity charOffset="1-13" id="DDI-PubMed.27128004.s9.e0" text="Ketoconazole" /><entity charOffset="53-64" id="DDI-PubMed.27128004.s9.e1" text="abiraterone" /><pair ddi="false" e1="DDI-PubMed.27128004.s9.e0" e2="DDI-PubMed.27128004.s9.e0" /><pair ddi="false" e1="DDI-PubMed.27128004.s9.e0" e2="DDI-PubMed.27128004.s9.e1" /></sentence><sentence text=" Rifampicin decreased abiraterone exposure by half"><entity charOffset="1-11" id="DDI-PubMed.27128004.s10.e0" text="Rifampicin" /><entity charOffset="22-33" id="DDI-PubMed.27128004.s10.e1" text="abiraterone" /><pair ddi="false" e1="DDI-PubMed.27128004.s10.e0" e2="DDI-PubMed.27128004.s10.e0" /><pair ddi="false" e1="DDI-PubMed.27128004.s10.e0" e2="DDI-PubMed.27128004.s10.e1" /></sentence><sentence text=" Hence, strong CYP3A4 inducers should be avoided or used with careful evaluation of clinical efficacy when administered with abiraterone acetate"><entity charOffset="125-144" id="DDI-PubMed.27128004.s11.e0" text="abiraterone acetate" /></sentence><sentence text="" /></document>